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I.  Introduction: Cellular Basis of Carcinogenesis  
Cancer is a disease of uncontrolled growth and proliferation whereby cells have 
escaped the body’s normal growth control mechanisms and have gained the ability to 
divide indefinitely. It is a multistep process that requires the accumulation of many 
genetic changes over time (Figure 1). These genetic alterations involve activation of 
proto-oncogenes to oncogenes, deregulation of tumour suppressor genes and DNA 
repair genes and ‘immortalisation’ which will be discussed in further detail in Sections 
I-IV of this chapter. 
 
 
Figure 1: Overview of the road to cancer. Cells may acquire mutations in genes that control 
proliferation, such as proto-oncogenes and/or tumor suppressor genes. Each new mutation 
may provide a selective advantage for this cell, leading to ‘clonal expansion’. Cellular 
properties changed in this process include cell cycle deregulation, apoptosis prevention and 
cell adhesion properties (CAMs – Cellular adhesion molecules). Image from Alison, MR, 
Cancer. Encyclopedia of Life Sciences, 2001 (DOI: 10.1038/npg.els.0001471). Reproduced 
with permission from John Wiley & Sons. 
 
 
1. Cell cycle regulation and the importance of apoptosis  
In normal cells, proliferation and progression through the cell cycle is strictly 
regulated by groups of proteins that interact with each other in a specific sequence of 
events (Figure 2). Checkpoints ascertain that individual stages of the cell cycle are 
completed correctly and ensure that incompletely replicated DNA is not passed onto 
daughter cells. Core to this control system are cyclin-dependent kinases (CDKs). 
CDKs are ‘master protein kinases’ that drive progression through the different phases 
of the cell cycle by phosphorylating and activating other downstream kinases. CDK 
activity is dependent on the presence of activating subunits called cyclins which are 
synthesised and degraded in a cell cycle-dependent manner. Cyclin-CDK complexes 
are further tightly regulated by CDK inhibitors. 
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Figure 2: Cyclins and cyclin-dependent kinases (CDKs) regulate the cell cycle. CDK’s 
and their regulatory subunits, cyclins (A, B, D & E) tightly control transition through the cell 
cycle. The brackets indicate the periods in which the cyclin-CDK complexes are active and 
orchestrate all events necessary in this period. The restriction point (R point) is a point in G1 
at which the cell becomes ‘committed’ to the cell cycle and after which extracellular 
proliferation signals are no longer required. ©2007 from The Biology of Cancer, 1
st
 ed. by RA 
Weinberg. Reproduced with permission of Garland Science/Taylor & Francis LLC.  
 
The re-entry of cells into the cell cycle is decided at the restriction point (R point). 
This decision is influenced by extracellular mitogenic signals which are transmitted 
via signalling pathways to key regulatory proteins such as transcription factors (e.g. 
E2F) in the nucleus (refer to Figure 3, Section II). These regulatory proteins ultimately 
activate the S-phase CDKs, which trigger the start of DNA synthesis. 
  
In normal cells, activation of another transcription factor, p53, often referred to as the 
‘guardian of the genome’, can impose cell cycle arrest and induce apoptosis 
(programmed cell death) through its ability to: 
 Induce the expression of cell cycle inhibitors to prevent proliferation of a cell until 
any damage has been repaired or 
 Initiate apoptosis, if the genomic damage is too great and cannot be repaired. 
In >50% of all human tumours the p53 pathway is aberrant. Inactivation of the p53 
protein renders it unable to signal and activate the cell’s apoptotic machinery 
resulting in increased survival of cancer cells.  
 
2. Cell immortalisation and tumourigenesis  
Immortalisation is defined as the acquisition of an infinite life span. Normal 
mammalian somatic cells proliferate a limited number of times before undergoing 
senescence. Senescent cells may remain metabolically active even though they have 
permanently ceased proliferation. Immortalisation is an essential step in the 
malignant transformation of normal cells and can be attributed, in part, to the 
presence of telomerase, the enzyme responsible for maintaining telomeres at the 
ends of chromosomes. By extending telomeric DNA, telomerase is able to counter 
the progressive telomere shortening that would otherwise lead to cell death. Unlike 
normal cells that lack detectable levels of telomerase activity, approximately 90% of 
human tumours consist of cells that contain an active telomerase enzyme.  
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II.   Cell Signalling in Carcinogenesis  
1.  Growth factors and their receptors  
Growth factors (GFs) play an important physiological role in the normal process of 
growth control aimed at maintaining tissue homeostasis. They transmit growth 
signals from one cell to another. These signals are sensed on the cell surface by 
specific growth factor receptors (GFRs). GFRs transfer the growth signal via 
signalling pathways to activate target molecules that promote proliferation (Figure 3).  
 
                                   
Figure 3: The MAP kinase pathway as an example of a growth signalling pathway.  
The mitogen (or growth factor) binds to its receptor, a receptor tyrosine kinase. Tyrosine 
phosphorylation of the receptor leads to activation of several docking proteins, and eventually 
to the activation Ras, bound to the inside of the cell membrane. Active Ras in turn activates 
the MAP kinase signalling cascade, beginning with Raf (not shown here). The final MAP 
kinase in this sequence activates several target proteins, for example a transcription factor 
that activates expression of the Myc gene. Myc itself is a transcription factor that activates the 
expression of cell cycle regulatory genes. ©2002 from Molecular Biology of the Cell, 4
th
 Ed. by 
Alberts et al. Reproduced with permission of Garland Science/Taylor & Francis LLC.   
 
Steps that characterise normal cell proliferation include: 
 The binding of a GF to its specific receptor on the cell membrane 
 Transient and limited activation of the GFR, which, activates several signal-
transducing proteins (e.g. Ras) on the inner leaflet of the plasma membrane 
 Transmission of the signal by signal transduction molecules, either to cytosolic 
targets or to the nucleus  where they activate transcription of specific genes 
 Entry of the cell into the cell cycle, ultimately resulting in cell division 
This pathway is often derailed in cancer and allows wayward cells to generate their 
own internal signals that stimulate proliferation and become independent of their 
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environments. Cancer cells are able to induce their own growth stimulatory signals 
when mutations in the GFR gene occur, which facilitates activation in the absence of 
GFs or when overproduction of GFs results in an autocrine signalling loop. 
 
2.  Other elements of cell signalling  
An alternative strategy by which cancer cells can become GF independent involves 
constitutive activation of internal signalling components. For example, the Ras protein 
in normal cells is switched off and does not signal unless a GFR becomes activated, 
which through a series of intermediaries, is able to activate the Ras protein, 
converting it from its quiescent state to an active, signal-emitting state. Thereafter, 
the Ras protein is able to release further downstream signals that are capable of 
inducing proliferation. In cancer cells, this signalling pathway is deregulated because 
structurally altered Ras proteins are able to continuously send growth stimulatory 
signals into the interior of the cell in the absence of GFs. 
 
III. Genes Frequently Mutated in Cancer  
The genes that have been implicated in carcinogenesis are divided into two broad 
categories oncogenes (‘cell accelerators’) and tumour suppressor genes (‘cell 
brakes’) but also include DNA repair genes (See section IV.3 for further detail).   
 
1. Cellular oncogenes  
Genes that promote autonomous cell growth in cancer cells are called oncogenes, 
and their normal cellular counterparts are called proto-oncogenes. Proto-oncogenes 
are physiologic regulators of cell proliferation and differentiation while oncogenes are 
characterised by the ability to promote cell growth in the absence of normal mitogenic 
signals. Their products, oncoproteins, resemble the normal products of proto-
oncogenes with the exception that oncoproteins are devoid of important regulatory 
elements. Their production in the transformed cells becomes constitutive, that is, not 
dependent on growth factors or other external signals. Proto-oncogenes can be 
converted to oncogenes by several mechanisms including point mutation and gene 
amplification resulting in: 
 Overproduction of growth factors 
 Flooding of the cell with replication signals 
 Uncontrolled stimulation in the intermediary pathways 
 Cell growth by elevated levels of transcription factors 
 
The RAS oncogene is the most frequently mutated oncogene in human cancer. It 
encodes a GTP-binding protein Ras that functions as an on-off ‘switch’ for a number 
of key signalling pathways controlling cellular proliferation. In a normal cell, Ras is 
transiently activated and recruits Raf, to activate the MAP-kinase pathway to transmit 
growth-promoting signals to the nucleus. The mutant Ras protein is permanently 
activated, leading to continuous stimulation of cells without any external trigger. Other 
oncogenes frequently mutated in cancer are listed in Table 1. 
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Table 1. Selected Oncogenes and Associated Cancers 
 
Category / Protein Function   
 Proto-
oncogene   
 Mode of 
Activation    Associated Cancer  
 Growth Factors           
 PDGF (β chain)   SIS    Overexpression    Astrocytoma, osteosarcoma     
 Fibroblast growth factors    HST-1    Overexpression    Stomach cancer   
    INT-2    Amplification    Bladder & breast cancer   
          Melanoma   
Transforming growth factor α   TGFα   Overexpression    Astrocytomas   
          Hepatocellular carcinomas   
 Growth Factor Receptors            
 EGF-receptor family    ERB-B1   Overexpression    SCC of the lung, gliomas   
    ERB-B2    Amplification    Breast and ovarian cancers   
 PDGF receptor    PDGF-R    Overexpression    Gliomas   
 Receptor for stem cell 
 (steel) factor    KIT    Point mutation    Gastrointestinal stromal tumours  
Proteins Involved in Signal 
Transduction            
 GTP-binding    K-RAS    Point mutation    Colon, lung, pancreatic tumours   
    H-RAS    Point mutation    Bladder & kidney tumours   
    N-RAS    Point mutation   Melanoma, leukaemia, lymphoma   
 Non-receptor tyrosine kinase    ABL    Translocation    CML, ALL  
 RAS signal transduction    BRAF    Point mutation    Melanomas   
 WNT signal transduction    β-catenin    Point mutation/    Hepatoblastomas & HCC 
       Overexpression   
 
Nuclear Regulatory Proteins            
 Transcriptional activators    C-MYC    Translocation    Burkitt lymphoma   
    N-MYC    Amplification   
 Neuroblastoma, small cell  
carcinoma of lung   
    L-MYC    Amplification    SCC of the lung   
 Cell-Cycle Regulators            
 Cyclins    CYCLIN D    Translocation    Mantle cell lymphoma   
       Amplification    Breast & oesophageal cancers   
    CYCLIN E    Overexpression    Breast cancer   
 Cyclin-dependent kinase    CDK4   
 Amplification or  
Point mutation   
 Glioblastoma, melanoma,   
sarcoma   
(adapted from Table 7-6, Kumar et al, Robbins & Cotran’s Pathological Basis of Disease, 8th ed. 
Elsevier 2010) 
 
 
2. Tumour suppressor genes  
Tumour suppressor genes (Table 2) encode proteins that are: 
 Receptors for secreted hormones that function to inhibit cell proliferation 
 Negative regulators of cell cycle entry or progression  
 Negative regulators of growth signalling pathways (e.g. APC or PTEN) 
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 Checkpoint-control proteins that arrest the cell cycle if DNA is damaged or 
chromosomes are abnormal 
 Proteins that promote apoptosis 
 DNA repair enzymes 
The transformation of a normal cell to a cancer cell is accompanied by the loss of 
function of one or more tumour suppressor genes and both gene copies must be 
defective in order to promote tumour development (see section VI.2). 
 
Table 2.  Examples of Tumour Suppressor Genes 
Gene Protein function Inherited Disease Spontaneous Tumours 
APC Negative regulator of the 
Wnt signalling pathway 
Adenomatous 
polyposis coli (APC) 
Most colon cancers 
BRCA1,  
BRCA2 
Components of DNA repair 
systems 
Familial breast and 
ovarian cancer 
Spontaneous breast cancers 
CDH1 E-cadherin, a cell adhesion 
molecule 
Hereditary diffuse 
gastric cancer 
Many epithelial cancers 
CDKN2A INK4a, inhibitor of cyclin-
dependent kinase Cdk4 
Some familial 
melanomas 
Some esophageal and 
pancreatic cancers 
MEN1 Transcription factor and 
protein kinase 
Multiple endocrine 
neoplasia 
Many metastatic cancers 
NF1 Neurofibromin, Ras-
GTPase activation 
Neurofibromatosis 
type 1 
Some tumors of neural crest 
origin 
PTEN Negative regulator of PI3K 
growth signalling pathway 
Cowden disease 30%-50% of spontaneous 
cancers 
RB Repression of transcription 
factor E2F 
Retinoblastoma, 
osteosarcoma 
Retinoblastoma, sarcomas, 
several carcinomas 
SMAD4 Signal transducer in TGF- 
signalling 
Juvenile polyposis Colon and pancreatic cancers 
TP53 Transcription factor; 
'guardian of the genome' 
Li-Fraumeni 
syndrome 
Most frequently mutated in 
human cancers 
TSC1, 
TSC2 
Inhibitor of mTOR Tuberous sclerosis Rare 
VHL Ubiquitin ligase von Hippel-Lindau 
disease 
Many renal cell carcinomas 
WT1 Transcription factor Wilms tumor Some leukaemias 
(Adapted from Table 7.1; Weinberg RA, Biology of Cancer, 1
st
 ed, Garland Science 2007)  
The retinoblastoma (Rb) protein is a tumor suppressor gene that controls the cell 
cycle transition from G1 to S Phase. Rb protein binds regulatory transcription factor 
E2F which is required for the synthesis of DNA replication enzymes. When Rb is 
bound to E2F, transcription/replication is blocked. The presence of growth factors 
(via the Ras pathway) activates cyclin-dependent kinase 4/6 (Figure 2) Active 
CDK4/6- phosphorylates and inhibits Rb, taking the brakes off E2F, and transition to 
S phase occurs. Disruption/deletion of the Rb gene therefore leads to uncontrolled 
cell proliferation.   
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IV. Causes of Cancer  
1. Mutations and cancer  
Cancer development is based on the accumulation of somatic mutations over 
lifetime. Germ line mutations are typically not involved, but in very rare cases of 
inherited cancer predisposition, they are contributing to disease progression. 
Typically the basal mutation rate is low in humans, but it may be enhanced through 
one of the three following groups of environmental carcinogens: chemical 
mutagens, radiation and tumour viruses.  Exposure to mutagens or radiation 
greatly increases the mutation rate and thus the probability of developing cancer.  
 Chemical mutagens comprise a quite disparate group of chemicals that modify 
DNA through a range of mechanisms, such as alkylation or deamination of DNA 
bases, or through intercalation between base pairs and formation of DNA adducts 
(e.g. aromatic hydrocarbons). Oxidative damage may also affect DNA integrity. 
 X-rays and radioactive radiation tend to induce DNA double-strand breaks, 
whereas UV radiation results in the formation of pyrimidine dimers, by cross-
linking of adjacent pyrimidine bases.  
 
Table 3  Human Tumour Viruses 
Virus (Group) Associated Human Cancer 
DNA VIRUSES   
Papilloma virus family   
Human papilloma virus (HPV) Genital tumours, squamous  
(various subtypes) cell carcinoma 
Herpes virus family   
Human herpes virus 8 (HHV8) Kaposi sarcoma 
Epstein-Barr virus (EBV) Burkitt's lymphoma,  Hodgkin's disease, 
  Nasopharyngeal carcinoma 
Hepadnavirus family   
Hepatitis B virus Hepatocellular carcinoma 
RNA VIRUSES   
Retrovirus family   
Human T-cell leukaemia virus Adult T-cell leukaemia  
Human immunodeficiency virus AIDS-related malignancies 
Flavivirus family   
Hepatitis C virus Hepatocellular carcinoma 
  
(Adapted from Table 43-1, Jawetz, Melnick & Adelberg’s Medical Microbiology, 24
th
 
ed. McGraw-Hill 2007)  
 
2. Viral causes of cancer  
Certain viruses, derived from quite different taxonomic groups (Table 3), are able to 
induce cancer development. We distinguish the highly oncogenic viruses, which 
contain viral oncogenes in their genomes that are in most cases derived from 
cellular proto-oncogenes, whereas slowly transforming viruses do not contain 
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such genes. They tend to use one of the following mechanisms to stimulate 
proliferation of their host cells:  
 Insertion of a strong promoter in the vicinity of a host cell proto-oncogene 
 Expression of proteins that neutralise host cell tumour suppressor proteins 
 Expression of proteins that prevent or delay apoptosis 
Characteristics of viral carcinogenesis include: 
 Tumour viruses often establish persistent infections in the human host 
 Host factors are important determinants of virus-induced carcinogenesis 
 Viruses are rarely complete carcinogens; they require additional factors to fully 
activate carcinogenesis. 
 
3. The importance of DNA repair systems  
Sophisticated DNA repair systems have evolved in order to maintain the human 
genome, by fixing damage that may have occurred to the DNA. Principal DNA repair 
mechanisms include: mismatch repair, base and nucleotide excision repair, 
repair of depurinated sites and repair of double-strand breaks. 
The importance of these repair systems for protection against accelerated 
mutagenesis and the development of cancer is impressively demonstrated through 
rare inherited cancer predisposition syndromes based on mutations in DNA repair 
enzyme systems (Table 4). 
 
Table 4   Inherited Diseases Caused by DNA Repair Defects 
Disease Protein Affected Affected Function 
Clinical 
Manifestation 
Bloom syndrome 13 different proteins Recombination repair? Immunodeficiency, 
cancer susceptibility, 
chromosome breaks 
Breast cancer 
susceptibility 
BRCA1, BRCA2; 
proteins of DNA 
repair complexes 
Homology-directed DNA 
repair 
Breast and ovarian 
cancer 
Cockayne 
syndrome 
Nucleotide excision 
repair protein 
Transcription-coupled 
nucleotide excision repair 
Poor growth, early 
senility,  neurological 
degeneration 
Fanconi anemia 8 different proteins Repair of DNA cross-links? Anaemia, leukaemia, 
chromosome 
breakage 
Hereditary 
nonpolyposis colon 
cancer (HNPCC) 
Proteins of mismatch 
repair 
Post-replication mismatch 
repair 
Cancer susceptibility 
Nijmegen breakage 
syndrome 
Activator of nuclear 
protein kinases 
Signalling for DNA double-
strand break repair 
Growth retardation, 
immunodeficiency, 
cancers 
Werner syndrome DNA helicase and 
exonuclease 
Unknown Premature aging,           
short telomeres 
Xeroderma 
pigmentosum 
Nucleotide excision 
repair proteins 
Genome-wide nucleotide 
excision repair 
Cutaneous 
photosensitivity 
(Adapted from Table 9.1, Meisenberg & Simmons, Principles of Medical Biochemistry, 3
rd
 ed. 
Mosby/Elsevier 2012) 
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V. Multistep Carcinogenesis  
Carcinogenesis can be considered as a complex micro-evolutionary process, which 
requires the accumulation of a range of (somatic) genetic mutations (Figure 1). Under 
selection pressure and through these mutations, cells acquire new characteristics, 
which provide them with an advantage in growth behaviour and other cellular 
properties, such as enhanced survival and invasiveness. This process is in most 
cases drawn out over many years and requires a series of individual steps. 
 
1. The main stages of carcinogenesis – an overview  
There are three major qualitative changes, which cells have to undergo in order to 
successfully proceed through the complete process of carcinogenesis, malignant 
transformation, invasion of neighbouring tissues and metastasis. Each one of 
these major stages comprises a series of genetic alteration of cells affecting specific 
genes that are involved in regulating cell properties relevant for the individual stage, 
i.e. growth behaviour (for malignant transformation), invasive properties and 
metastatic potential. 
 
2. Early steps characterised in colon cancer  
The best characterised example supporting the theory of multi-step carcinogenesis is 
colorectal cancer. This is largely due to the relative accessibility of colon cancer 
samples and due to the availability of the distinct histo-morphological description of 
early stages of cancer development. Genetic characterisation of a large number of 
early, intermediate and late adenomas and frank carcinomas led to the establishment 
of a ‘preferred’ sequence of genetic alterations during the adenoma-adenocarcinoma 
pathway of colorectal cancer (Figure 4). These include the activation of the K-ras 
oncogene from its cellular proto-oncogene (pink letters) and the loss for three tumour 
suppressor genes (blue letters), where loss of APC (adenomatous polyposis coli) is 
an early event, whereas loss of p53 is normally a late event.   
  
 
 
Figure 4: Genetic events in early colon carcinoma progression. Approximate correlation 
of early genetic events in the development of colon carcinoma (the adenoma-adeno-
carcinoma pathway) with histopathological features. Note that clinical staging typically refers 
to the later observations and cannot be correlated with the genetic events. Genetic events are 
indicated by vertical arrows and colour-coded as follows: Blue: loss of tumour suppressor 
gene (TSG) function, red: activation of oncogenes, green: epigenetic events. The sequence of 
genetic events is not necessarily obligatory, but loss of APC is typically the first event and 
loss of p53 typically the last one.  ©2007 from The Biology of Cancer, 1
st
 ed. by Weinberg. 
Reproduced with permission of Garland Science/Taylor & Francis LLC. 
11 
 
 
3. Cellular principles of invasion and metastasis  
The spread of cancer cells to distant sites in the body via the blood 
stream/lymphatics is known as metastasis and is the most lethal form of the disease 
(Figure 5). Metastatic cells are less adhesive than normal cells and are able to 
degrade and penetrate tissue barriers such as the extracellular matrix (ECM) of 
surrounding connective tissue and the basement membrane of blood vessels. After 
gaining access to the systemic circulation they can invade normal tissue at various 
sites in the body forming secondary colonies. The invasion - metastasis cascade 
involves: 
 acquisition of local invasiveness (1) 
 invasion of the cell into blood/ lymph vessels (intravasation) (2) 
 transport through the blood/lymph vessels to distant tissue sites (3) 
 escape of the cancer cells from circulation (extravasation) (4) 
 ability to adapt to the local tissue environment and to proliferate (5) 
 
 
 
Figure 5: Steps involved in the metastatic cascade. During metastatic progression, tumour 
cells exit their primary sites of growth (local invasion, intravasation; 1 & 2), translocate 
systemically (survival in the circulation, arrest at a distant organ site, extravasation; 3 & 4), 
and adapt to survive and thrive in foreign microenvironments (5). Adapted from Valastyan S 
and Weinberg RA, Cell 147, 275-292, 2011. 
 
Epithelial-mesenchymal transition (EMT) is a key transition enabling cancer cells 
to become motile and invasive, and ultimately form metastases in distant tissues. 
Cell motility is regulated by small G proteins that are activated by cytoplasmic 
signalling pathways controlling the assembly of new actin cytoskeleton. Cell 
invasiveness is enhanced through overexpression of various matrix 
metalloproteinases (MMPs) that degrade components of the ECM. 
 
Angiogenesis, the growth of the new blood vessels, is necessary for solid tumours 
to continue growing beyond a certain size. More than a dozen different proteins and 
several small molecules are released by tumours as signals for angiogenesis. Two 
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proteins most important for sustaining tumour growth are vascular endothelial growth 
factor (VEGF) and basic fibroblast growth factor (bFGF). 
 
4. Stromal microenvironment and carcinogenesis  
Cross talk between stromal cells within the ECM and tumour cells is also vital for 
carcinogenesis. The following factors are thought to contribute to malignant 
transformation: 
 Cleavage of matrix components releases angiogenic factors (VEGF) promoting 
new vessel growth and proteolytic fragments that favour cancer cell motility. 
 The ECM stores GFs in inactive forms, which are released by active matrix 
proteases and stimulate the growth of tumour cells in a paracrine manner. 
 Stromal cells within the ECM may directly transmit oncogenic signals to tumour 
cells. 
 
VI. Other Genetic Aspects of Cancers  
Apart from the three major types of genes frequently altered in cancer, i.e. tumour 
suppressor genes, proto-oncogenes and DNA repair genes, there are several other 
genetic alterations observed in tumours, which will be briefly described here. 
 
1. Genetic instability of tumour cells  
Genetic analysis of solid tumours revealed the presence of a high degree of genetic 
abnormalities, such as aneuploidy, chromosome translocations etc. This is likely due 
to the lack of active p53 protein, and the ability of cancer cells to avoid cell death 
through apoptosis. Other mechanisms may also play a part here, e.g. mitotic defects 
that result in chromosome miss-segregation. Chromosomal instability (CIN) is 
widespread in cancer cells from epithelial origin, but much rarer in haematopoietic 
tumours. 
 
2. Alteration of genetic mechanisms in cancer  
Three different alterations of genetic mechanisms often observed in cancer will be 
briefly explained below.  
Loss of heterozygosity (LOH) describes a genetic phenomenon often seen with 
tumour suppressor genes in cancer. Since the human karyotype is diploid, mutation 
of one allele of a tumour suppressor gene is not sufficient to cause cancer. In 
heterozygous individuals, the wildtype allele will provide for a functional phenotype. 
However, when a ‘second hit’ occurs, e.g. through missegregation of chromosomes, 
this individual (or cell) may lose its ‘heterozygosity’, leading to a full cancerous 
phenotype. Genetic analyses of LOH helped to identify the chromosomal location of 
many tumour suppressor genes. 
Microsatellite instability (MIN) is a phenomenon often seen in colorectal cancer 
cells with defective DNA mismatch repair system, e.g. in hereditary nonpolyposis 
colorectal cancer (HNPCC). Microsatellites are regions of repetitive DNA sequences 
in the genome that are prone to shortening or extension if the mismatch repair 
enzymes are defective. Genetic analysis of these regions can be used to identify 
such defects.  
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DNA hyper- or hypomethylation. DNA methylation of gene promoter regions on 
CpG (cytosine-phosphate-guanine) sequences is an important epigenetic control 
mechanism to silence specific genes. In cancer, DNA hypermethylation is often 
involved in the silencing of tumour suppressor genes. Conversely, DNA 
hypomethylation may contribute to the activation of oncogenes, although the former 
occurs much more commonly.  
 
3. Inherited predisposition to cancer  
Whilst cancer as such is not inherited, there are a wide range of rare familial 
syndromes that predispose affected family members to cancer development. We 
mentioned above cancer predisposition syndromes that are based on mutations in 
DNA repair enzyme systems (Table 4). A by far larger number of familial cancer 
syndromes is based on mutations of tumour suppressor genes, of which a selection 
is shown in Table 2. It is interesting to note that germ-line mutations of activated 
oncogenes are normally not inherited. They may arise during gametogenesis, but the 
mutant alleles are typically dominant at the cellular level, which results in disturbance 
of normal embryonic development, and reduced viability of these embryos. 
Fortunately, the inherited cancer predisposition syndromes listed in Tables 2 and 4 
are extremely rare diseases, but they represent powerful illustrations for the 
importance of DNA repair and tumour suppressor genes for maintaining body 
homeostasis. 
 
4. Principal applications of genetic testing in cancer  
As an increasing number of cancer-related genes or gene mutations is characterised, 
the potential of DNA and RNA expression testing for cancer-related applications is 
being explored. Principal applications include: 
Gene mutation screening in families with inherited cancer predisposition 
syndromes, which identifies at-risk individuals in such families and allows for 
decisions to be made about early disease monitoring, aggressive treatment regimens 
and prophylactic surgery (e.g. mastectomy in familial breast cancer).  
Gene expression microarray analysis can be used for classification of cancer 
subtypes, e.g. in breast cancer or for the distinction between acute lymphoblastic and 
acute myeloid leukaemia. Other applications include the diagnosis of benign vs. 
malignant tumours or the monitoring of response to therapies. 
 
VII. Modern Treatment Modalities Arising from Cancer Cell Biology   
1. Tumour immunology and immunotherapy  
The immune system is able to launch attacks not only against foreign invaders, but 
also against body cells that may display ‘foreign’ antigens, such as cancer cells. The 
‘immune surveillance theory’ is supported by the observation that the incidence of 
certain cancers is drastically increased in immune-compromised patients. Tumour 
cells may be recognised by the immune system through the expression of tumour-
associated antigens, but the antigenicity varies considerably between different types 
of antigens.  
In order to avoid an attack by the immune system, tumour cells use a range of 
strategies, such as suppression of expression of tumour-associated antigens or of 
MHC class 1 molecules, or even counterattack against immune cells. 
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Research into immunotherapy of cancers aims to devise novel strategies to 
support the anti-cancer immune response; principal approaches include:  
 Antigen-independent cytokine therapy (e.g. interleukins or interferons) 
 Stimulating cell-mediated immune responses (adoptive T-cell transfer, vaccines) 
 Passive immunotherapy using monoclonal antibodies (e.g. Herceptin, Rituxan). 
 
2. Novel approaches arising from cancer cell biology 
The progress in our knowledge about gene mutations frequently occurring in 
cancers, combined with the development of modern molecular biology methods has 
led to both new diagnostic tools (see section VI. 4.) and new treatment modalities 
that have shown some success in the management of selected types of cancers. 
The knowledge about cancer–associated genes and their role in cellular growth 
signalling pathways has led to the development of a considerable number of anti-
cancer drugs targeting such signalling pathways: 1) monoclonal antibodies that 
target the extracellular domains of growth factor receptors and 2) small-molecule 
inhibitors, targeting either receptor tyrosine kinases or other components of growth 
signalling pathways, such as Ras, b-Raf or mTOR (Figure. 6). Two examples of 
such successful anti-cancer agents are the monoclonal antibody Herceptin for the 
treatment of a specific subtype of breast cancer, and the small-molecule inhibitor 
Gleevec targeting the fusion protein Bcr-abl, a mutant tyrosine kinase, involved in 
the development of chronic myeloic leukaemia (CML). A third group of potential 
drug targets are some anti-apoptotic proteins that are frequently overexpressed in 
cancer cells.  
           
 
Figure 6:  Targets of novel anti-cancer drugs in cellular growth signalling pathways. 
The cell membrane is indicated in light grey, red diamonds represent growth factors, green 
shows the growth factor receptor with the intracellular tyrosine kinase domain (Tk) indicated 
by the red circle. Coloured rectangles symbolise signalling components belonging to specific 
pathways (blue: PI3K/Akt pathway; ochre: Ras/MAP kinase pathway). Dotted (black) arrows 
point to cell biological outcomes of these pathways. Groups of novel anticancer drugs and 
their targets are shown in red.  
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VIII. Summary: The Hallmarks of Cancer    
To summarise the core points, we are listing the ‘hallmarks of cancer’, which 
describe the biological capabilities acquired by cells during the multistep 
development of human tumours (Figure 7): 
  
 
Figure 7: A summary of the six hallmarks of cancer. Additional capabilities crucial to 
cancer phenotypes that are not shown here include defects in DNA repair mechanisms and 
signalling interactions of the tumour microenvironment. Image sourced from Hanahan, D and 
Weinberg, RA, Cell 144, 646-674, 2011. 
 
 Self-sufficiency in growth signals: Tumours have the capacity to proliferate 
without external stimuli, usually as a consequence of oncogene activation. 
 Insensitivity to growth-inhibitory signals: Tumour cells may not respond to 
molecules that are inhibitory to the proliferation of normal cells.  
 Evasion of apoptosis: Tumours may be resistant to programmed cell death, 
as a consequence of inactivation of p53 or overexpression of anti-apoptotic 
proteins. 
 Defects in DNA repair: Tumours may fail to repair DNA damage caused by 
carcinogens or unregulated cellular proliferation.  
 Limitless replicative potential: Tumour cells have unrestricted proliferative 
capacity, associated with maintenance of telomere length and function. 
 Sustained angiogenesis: Tumours are not able to grow without formation of 
a vascular supply, which is induced by various factors, the most important 
being vascular endothelial growth factor (VEGF). 
 Ability to invade and metastasise: Tumour metastases are the cause of the 
vast majority of cancer deaths and depend on processes that are intrinsic to 
the cell or are initiated by signals from the tissue microenvironment. 
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